DM
RNAC icon

Deerfield Management’s Cartesian Therapeutics RNAC Stock Holding History

Deerfield Management’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-31,721
Closed -$17.4M – 101
2017
Q3 		$17.4M Sell
31,721
-3,612
-10% -$1.92M 0.78% 39
2017
Q2 		$21.1M Hold
35,333
– – 1.12% 27
2017
Q1 		$15.2M Buy
35,333
+6,893
+24% +$2.9M 0.59% 53
2016
Q4 		$14.6M Buy
+28,440
New +$16.6M 0.6% 50

Other funds holding RNAC

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
SRF
Silver Rock Financial Los Angeles, California $49.7M AUM 17.42% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Deerfield Management's RNAC Position: Q4 2017 in Review

Deerfield Management sold out of Cartesian Therapeutics (RNAC) in Q4 2017, closing a stake of 31,721 shares — an estimated $17.4M sold.

Deerfield Management first reported a position in RNAC in Q4 2016 and held it in 4 quarters. The position peaked at $21.1M in Q2 2017. 63 funds tracked by Wall St. Rank hold RNAC as of Q4 2017.

  • Deerfield Management reported no remaining Cartesian Therapeutics position as of Q4 2017 after selling out during the quarter.
  • Deerfield Management sold 31,721 Cartesian Therapeutics shares in Q4 2017, an estimated $17.4M.
  • Deerfield Management first reported a position in Cartesian Therapeutics in Q4 2016 and held it in 4 quarters.
  • Deerfield Management's Cartesian Therapeutics position peaked at $21.1M in Q2 2017.
  • 63 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q4 2017.

Based on Deerfield Management's 13F filing for Q4 2017, filed 14 Feb 2018.